TG Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
TG Therapeutics has a total shareholder equity of $160.5M and total debt of $100.5M, which brings its debt-to-equity ratio to 62.6%. Its total assets and total liabilities are $329.6M and $169.1M respectively. TG Therapeutics's EBIT is $20.6M making its interest coverage ratio 1.6. It has cash and short-term investments of $217.5M.
Key information
62.6%
Debt to equity ratio
US$100.48m
Debt
Interest coverage ratio | 1.6x |
Cash | US$217.51m |
Equity | US$160.50m |
Total liabilities | US$169.09m |
Total assets | US$329.59m |
Recent financial health updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe
Feb 08TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue
Jan 28TG Therapeutics: Elucidating The Upcoming Binary Event
Dec 27Financial Position Analysis
Short Term Liabilities: TGTX's short term assets ($317.9M) exceed its short term liabilities ($53.7M).
Long Term Liabilities: TGTX's short term assets ($317.9M) exceed its long term liabilities ($115.4M).
Debt to Equity History and Analysis
Debt Level: TGTX has more cash than its total debt.
Reducing Debt: TGTX's debt to equity ratio has increased from 0.3% to 62.6% over the past 5 years.
Debt Coverage: TGTX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: TGTX's interest payments on its debt are not well covered by EBIT (1.6x coverage).